Table 2.

Basic characteristics of the cohort of patients from BENEFIT with at least one 25(OH)D measurement

Characteristic	Value
N	465
Age, years ± SD	31.3 ± 7.5
Female sex, n (%)	329 (71)
Number of patients with at least 1 GEL at the CIS, n (%)	196 (42)
Number of patients with at least 1 GEL during the first 24 months, n (%)	262 (56)
IFNB-1b treatment at day 1, n (%)	0 (0)
IFNB-1b treatment at month 24, n (%)	303 (78)

BENEFIT, Betaferon/Betaseron in Newly Emerging For Initial Treatment; 25(OH)D, 25-hydroxyvitamin D; SD, standard deviation; GEL, gadolinium-enhancing lesion; CIS, clinically isolated syndrome; IFNB-1b, interferon beta-1b.